ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
107.48
-12.30 (-10.27%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close119.78
Open120.00
Bid107.50 x 1000
Ask108.68 x 900
Day's Range106.56 - 120.57
52 Week Range56.76 - 131.87
Volume2,300,879
Avg. Volume556,774
Market Cap3.518B
Beta (3Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the positive results from the interim analysis of the Phase 3 REGENERATE study of obeticholic acid (OCA) in patients with fibrosis due to nonalcoholic steatohepatitis (NASH) have been published in The Lancet. This is the first peer-reviewed publication of positive results from a pivotal study evaluating an investigational therapy for NASH. “The first positive Phase 3 study results in NASH represent a real watershed moment for the hepatology field,” said Zobair M. Younossi, M.D., Professor and Chairman of the Department of Medicine at Inova Fairfax Medical Campus, Chair of the REGENERATE Steering Committee and a lead author of the publication.

  • GlobeNewswire

    Intercept Pharmaceuticals Appoints Jason Campagna as Chief Medical Officer

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jason Campagna, M.D., PhD., as Chief Medical Officer. In his new role, Dr. Campagna will provide strategic medical and scientific oversight for Intercept, and work in close collaboration with the company’s Research & Development, Regulatory, Medical Affairs and Safety & Pharmacovigilance departments. “Jason has proven to be an outstanding leader in his role overseeing our industry-leading NASH clinical development program over the past three years,” said Dr. Pruzanski.

  • GlobeNewswire

    FDA Accepts Intercept’s NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted Intercept’s New Drug Application (NDA) for obeticholic acid (OCA) seeking accelerated approval for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH) and granted priority review. The FDA grants priority review to drugs that have the potential to treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness.

  • GlobeNewswire

    New REGENERATE Interim Analysis Data Presented at The Liver Meeting® Report OCA Improved Multiple Noninvasive Markers of Liver Fibrosis in Patients with NASH

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional supportive data from the first reported analyses of the Phase 3 REGENERATE study examining the effects of obeticholic acid (OCA) on noninvasive assessments of liver fibrosis and patient-reported outcomes (PROs). Patients in the REGENERATE primary intent-to-treat (ITT) population (n=931) with stage 2 and 3 fibrosis were randomized 1:1:1 to receive OCA 25 mg (n=308), OCA 10 mg (n=312) or placebo (n=311) once daily over 18 months. As previously reported, in the primary efficacy analysis, once-daily OCA 25 mg met the primary endpoint of fibrosis improvement (≥1 stage) with no worsening of NASH in 23.1% of patients compared to 11.9% of placebo patients at the planned 18-month interim analysis (p=0.0002 vs. placebo).

  • GlobeNewswire

    Intercept Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    Worldwide Ocaliva net sales of $61.5 million in the third quarter of 2019 representing 32% growth versus the prior year quarter; increasing full year 2019 worldwide Ocaliva net.

  • GlobeNewswire

    Intercept to Announce Third Quarter 2019 Financial Results on November 5, 2019

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2019 financial results prior to market open on Tuesday, November 5, 2019. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

  • GlobeNewswire

    Intercept Announces New NASH and PBC Data to be Presented at The Liver Meeting® 2019

    New analyses from Phase 3 REGENERATE study evaluating the effects of OCA on non-invasive liver fibrosis tests and NASH patient-reported outcomes Five-year analysis of long-term.

  • GlobeNewswire

    Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASH

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Adminstration (FDA) for obeticholic acid (OCA) for the treatment of patients with fibrosis due to nonalcoholic steatohepatitis (NASH).

  • GlobeNewswire

    Intercept to Present at Upcoming Investor Conference in October

    NEW YORK, Sept. 25, 2019 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.

  • GlobeNewswire

    Intercept Launches NASHTRUTH.com, an Online Educational Resource for People with Advanced Fibrosis Due to NASH

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the launch of NASHTRUTH.com, a new online educational resource for people with advanced fibrosis due to NASH. NASHTRUTH.com was developed in collaboration with people living with NASH and leading liver patient advocacy organizations. NASHTRUTH.com features information about the risks of disease progression, key findings from a recent NASH disease state survey that has identified critical gaps in knowledge about the disease and personal stories from people living with NASH.

  • GlobeNewswire

    Intercept Appoints Lisa DeFrancesco as Vice President, Investor Relations

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Lisa DeFrancesco as Vice President, Investor Relations. “Lisa brings nearly 20 years of experience to the Intercept team,” said Sandip Kapadia, Chief Financial Officer of Intercept. Ms. DeFrancesco joins Intercept from Melinta Therapeutics where she served as Senior Vice President, Investor Relations, Corporate Communications and Government Affairs and sat on the company’s executive leadership team.

  • GlobeNewswire

    Intercept to Present at Upcoming Investor Conferences in September

    NEW YORK, Aug. 23, 2019 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.

  • GlobeNewswire

    Intercept Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

    Company delivers strongest quarter to date with worldwide Ocaliva® net sales of $65.9 million in the second quarter of 2019, representing 53% growth versus the prior year.

  • GlobeNewswire

    Intercept to Announce Second Quarter 2019 Financial Results on August 7, 2019

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2019 financial results prior to market open on Wednesday, August 7, 2019. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

  • GlobeNewswire

    Intercept to Present at Upcoming Investor Conferences in June

    NEW YORK, May 30, 2019 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.

  • GlobeNewswire

    Intercept to Present at Upcoming Investor Conferences in May

    NEW YORK, May 10, 2019 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.

  • GlobeNewswire

    Intercept Pharmaceuticals Announces Proposed Offerings of $200 Million of Common Stock and $200 Million of Convertible Senior Notes due 2026

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it is commencing an underwritten public offering to sell, subject to market and other conditions, up to $200 million of its common stock. Intercept also announced that it is commencing an underwritten public offering to sell, subject to market and other conditions, up to $200 million aggregate principal amount of convertible senior notes due 2026 (the “Notes”).  The Notes will be senior unsecured obligations of Intercept and will mature on May 15, 2026, unless earlier converted, redeemed or repurchased.

  • GlobeNewswire

    Intercept Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended March 31, 2019. “Our Phase 3 REGENERATE readout demonstrating OCA’s anti-fibrotic benefit in patients with NASH has been a watershed moment for the liver community and underscores our unique competitive opportunity to become the first approved NASH therapy,” said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept.

  • GlobeNewswire

    Intercept to Announce First Quarter 2019 Financial Results on May 8, 2019

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2019 financial results prior to market open on Wednesday, May 8, 2019. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

  • GlobeNewswire

    Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional supportive data from its pivotal Phase 3 REGENERATE study of obeticholic acid (OCA) in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH). The new data based on additional analyses show that OCA demonstrated robust efficacy across a range of additional histologic and biochemical parameters. “Halting or reversing fibrosis is a central therapeutic objective for patients with NASH, so the results from the 18-month interim analysis of REGENERATE are highly meaningful and clinically important,” said Zobair M. Younossi, M.D., PhD, Professor and Chairman of the Department of Medicine at Inova Fairfax Medical Campus, Professor of Medicine at Virginia Commonwealth University, Inova Campus and the Chair of the REGENERATE Steering Committee.

  • GlobeNewswire

    Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019

    NEW YORK, April 04, 2019 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.

  • GlobeNewswire

    Intercept to Present at Upcoming Investor Conferences

    NEW YORK, March 05, 2019 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.

  • GlobeNewswire

    New Research: Key Drivers of Growth for American Tower Corporation (REIT), Lowe's Companies, Mimecast, Live Nation Entertainment, Intercept Pharmaceuticals, and Coherus BioSciences — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • GlobeNewswire

    Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Issues 2019 Financial Guidance and Provides Business Update

    Positive topline results from pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH: the largest and first successful pivotal Phase 3.